Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials.

Front Neurosci · 2021 · PMC8441015 · PMID 34539340

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Correlating with this, the CSF biomarker phosoho-tau-181 showed a decreasing trend with Bapineuzumab treatment, however, no difference was observed in Aβ at 78 weeks ( Salloway et al., 2009 ).

also in 47,180 other papers

showed a trendno p-value reported

DAD and MMSE tests showed a trend toward improvement in function and cognition between 50 and 78 weeks.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.